Kaplan-Meier estimates of RS survival according to TP53 status. (A) RS with TP53 mutations showed a significantly shorter survival (Events/N, 24/31; median, 10.0 months; 95% CI, 6.6-13.3 months) compared with RS devoid of TP53 mutations (Events/N, 30/52; median, 27.0 months; 95% CI, 8.5-45.4 months; P = .008). (B) RS with 17p13 deletion showed a significantly shorter survival (Events/N, 23/28; median, 10.0 months; 95% CI, 3.0-17.0 months) compared with RS devoid of 17p13 deletion (Events/N, 31/55; median, 35.8 months; 95% CI, 7.1-64.6 months; P < .001). (C) RS with TP53 disruption by deletion and/or mutation showed a significantly shorter survival (Events/N, 32/40; median, 9.4 months, 95% CI: 4.6-14.2 months) compared with RS without TP53 disruption (Events/N, 22/43; median, 47.1 months; 95% CI, 6.9-87.3 months).